Pharmaceutical Drugs Archives - Business Intelligence

Tag: Pharmaceutical Drugs

Pharmaceutical Value Chain + Market Intelligence

Restoring Normalcy in the Pharmaceutical Value Chain: The Impact of COVID-19 and the Next Step to Success

The COVID-19 pandemic has challenged industries, countries, and governments endlessly over recent months. The spread of the virus has led to a range of issues that impact the foundation and functioning of business operations, GDPs’, and supply chains. All industries are now working towards recovery, and the pharmaceutical industry is attempting to regain control and functionality across the pharmaceutical value chain.

The pharmaceutical value chain includes every component and every process from manufacturer to end-consumer. This includes, but is not limited to, manufacturing, acquiring regulatory approval, import and export, distribution, and retail. The safety regulations, nationwide lockdowns, and transportation disruptions caused by the COVID-19 pandemic are among the biggest factors impacting the pharmaceutical value chain.

Pharmaceutical companies have attempted to develop more streamlined processes and taken various initiatives prior to the COVID-19 pandemic due to the pharmaceutical value chain’s fragmented nature. However, few have succeeded, and the different strategies utilized by companies did not protect the value chain from the hard-hitting impact of the COVID-19 pandemic.

As the pharmaceutical industry focuses its effort towards recovering the pharmaceutical value chain, companies must understand the impact of the pandemic. Therefore, in this article, Infiniti’s market intelligence experts detail the effects of the COVID-19 crisis on the pharmaceutical value chain. Additionally, they discuss the best path to recovery for pharmaceutical companies and highlight the value of market intelligence solutions in this attempt to return to normalcy.

The pharmaceutical industry is on the path to recovery and companies need to strategize for the changing market dynamics and impact of the COVID-19 pandemic. Speak to our industry experts to learn how companies can develop the optimal strategies to face these challenges.

Impact of COVID-19 on the Pharmaceutical Value Chain

As is the case with most industries, there have been innumerable problems posed by the advent of the COVID-19 pandemic in the pharmaceutical value chain. However, three major segments have been severely impacted and will need the most focus and recovery strategies from pharmaceutical companies. The impact of the COVID-19 pandemic on the pharmaceutical value chain can be witnessed in the following three segments:

Pharmaceutical Value Chain + Market Intelligence

APIs and the Dependence on APAC Countries

The pharmaceutical industry’s raw material supply chain was disrupted by the high dependence of pharmaceutical companies on China and India. The two APAC countries source a majority segment of the active pharmaceutical ingredients (APIs), intermediates, and reagents required by pharma companies. Since China was the first infected country, the raw material supply chain was slightly challenged. However, the spread of the virus has impacted India severely and caused a major disruption in the pharmaceutical value chain.

While China is on the path to recovery and is attempting to return to normalcy, India has many obstacles to overcome before it can successfully overcome the impact of the COVID-19 crisis. Restoring operations and recovering from the effects of the pandemic will cost the pharmaceutical value chain a substantial amount of time and effort due to this factor.

Logistics and Distribution Challenges

Countries across the globe have announced nationwide lockdowns and severely limited domestic and international transportation. Although this step was crucial for the containment of this deadly virus, it has led to major logistical challenges across industries. The pharmaceutical value chain has been similarly impacted due to transportation and distribution limitations.

The fragmented nature of the pharmaceutical value chain is one of the reasons the transportation restrictions are impacting the industry severely. The process involves the procurement of various raw materials from different locations in the APAC, North American, and European regions. Additionally, the manufacturing, packaging, distribution, and retailing are conducted in various areas. With the continuous spread of the virus and government restrictions on population movement and transportation, pharmaceutical companies need to evaluate their distribution and logistics strategies to maintain business continuity.

Paused Clinical Trials and the Drug Development Process

A large number of clinical trials worldwide have been suspended, postponed, or halted since the advent of the COVID-19 pandemic. Stakeholders consider this the most impacted segment in the pharma industry. Due to the need for social distancing, the limitations on transport, and the requirements of new hygiene protocols, conducting clinical trials and collecting real-world evidence has been challenging for pharma companies. The halting of clinical trials translates into a delay in the development and time-to-market for various therapies and drugs.

Simultaneously, pharmaceutical companies are struggling to conduct clinical trials to develop a vaccine for the SARS-CoV-2 virus, which causes COVID-19. However, they face challenges finding ideal candidates and carrying out their clinical trials despite the various limitations. Pharma companies and governments are working towards digitalizing the clinical trial process with innovative alternatives such as telemedicine and mailing trial drugs. Efficiently digitalizing, and overcoming the various challenges caused by the COVID-19 pandemic will help companies develop a vaccine and fast-track recovery worldwide.

Understanding the impact of the COVID-19 pandemic on the pharmaceutical value chain is a crucial step for recovery in the pharmaceutical industry. Request more information to gain more in-depth insights into the challenges caused by the pandemic and the next step to recovery.

How can Market Intelligence Solutions help Pharmaceutical Companies Overcome the Impact of COVID-19?

Pharmaceutical companies need a series of solutions to assist them in their attempt to recover from the impact of the COVID-19 pandemic. The pharmaceutical value chain has been significantly disrupted through 2020, and by re-establishing normalcy soon, companies can minimize the long-term implications of the pandemic across the value chain.

Infiniti’s market intelligence solutions can provide companies with insights, guidance, and strategies to help their industry recover as quickly as possible. There are various crucial factors that pharma companies must focus on during the process of recovery, and Infiniti’s market intelligence solutions can help them adapt and recuperate as required. Our market intelligence experts can help pharma companies and the pharmaceutical value chain in the following crucial ways:

  • Companies must improve transparency on the various levels of the supply chain and identify alternative sources for the different raw materials or services that are unavailable. Infiniti’s demand planning solutions enable companies to provide visibility into their operations and supply chains required to make real-time decisions and keep stakeholders informed.
  • There is also an increasing need for companies to analyze their inventory, estimate the available inventory across the value chain, and attempt to continue production and delivery to customers. With Infiniti’s inventory management solutions, companies can try to fulfill customers’ demands despite the disruptions caused by the COVID-19 pandemic.
  • Pharmaceutical companies must also focus on understanding and strategizing for the changing demands of their consumers. With social distancing and new hygiene protocols, consumers have been less likely to renew their prescriptions. Infiniti’s demand management solutions can enable companies to predict, plan, and meet customer demands accurately.

The pharmaceutical industry can successfully recover the pharmaceutical value chain with efficient planning, management, and strategizing. Infiniti’s market intelligence solutions provide companies with the data-driven insights and expert guidance they require to efficiently overcome the impact of the COVID-19 pandemic across the value chain.

Infiniti’s market intelligence solutions can serve as the differentiator between a quick recovery and additional challenges for companies attempting to recover the pharmaceutical value chain. Request a free proposal to enter the post-COVID era as a pharmaceutical industry champion with our expert insights and guidance.

Pharma logistics

Identifying Critical Pharma Logistics Challenges in Canada

Every business endures pressure in terms of strict delivery schedules and meeting production efficiency. But when it comes to pharmaceuticals and healthcare product manufacturers, these deadlines become a matter of life and death, due to which ensuring product quality and timely deliveries are paramount for companies operating in this sector. This necessitates them to incorporate a changeover from existing pharma logistics strategies and traditional supply chain practices to new and innovative techniques to improve efficiency. Furthermore, in order to be adequately equipped to distribute pharmaceutical and healthcare products across Canada, pharma companies must be fully aware of the pharma logistics pain-points that the market has to offer.

As research and technology continue to fundamentally transform pharma capabilities, pharma logistics is being forced to adapt to changes in the types of products brought to the market. Request a free proposal to know how our experts can help you adapt to the changing trends in the pharma industry.

Large territories

Cold chains used for pharma logistics in Canada need to be highly robust due to the region’s vast territories. The region’s immense landscape provides challenging driving conditions including long distances, mountain winter conditions in the west, and unexpected weather scenarios that can result in roadblocks to effective delivery such as bridges ruined by rain, roads blocked by ice, and many other hazards. All of these factors have the potential to not only add to major transit delays but can also result in significant costs. Moreover, it can also prove to be difficult for pharma logistics providers to reach places up in the north due to limited infrastructure. In such territories, it may not be possible to place the pharmaceutical products on a direct flight to the required location, so the medicine may need to travel via truck for two days to complete the journey safely.

Extreme weather conditions

Temperatures can sometimes soar to extremes in Canada and this can sometimes compromise the quality of pharma products during transit. The pharma logistics facilities used must be able to protect the products from overheating in the hot climates or from freezing in the cold climates. This places a heavy burden on validating quality systems within the chain. The unpredictability of the weather conditions in Canada, in terms of their severity and duration, makes it extremely challenging for pharma logistics providers to preserve and ensure the quality and timely delivery of products.

Few industries face the scrutiny and demand for excellence as those engaged in pharma manufacturing. Get in touch with us to know more about our solutions for pharma companies and learn how we can help you stay in line with the advancements in the pharmaceutical industry.

Partnerships and collaborations

The pharmaceutical industry in Canada is rapidly moving towards an externalized R&D set up through partnerships and collaborations. A similar trend has been noted in the pharma logistics segment with several manufacturers outsourcing supply chain processes in an effort to benefit from the expertise of pharma logistics providers. However, this comes with challenges of its own. By delegating responsibilities externally, pharma manufacturers risk losing the end-to-end control that they once had on all their operations. Therefore, a stringent and robust quality agreement must be formed between all parties to protect the integrity of the product. Particularly well-defined standard operating procedures must be established regarding how the product and the raw materials will be treated. Cold chain partnerships with pharma logistics companies are largely a matter of trust. Once the cargo is handed to a forwarder or carrier, shippers must rely on their partners to safely steward their temperature-sensitive products through the cold chain. The success of these partnerships relies on effective communication. The best way to ensure effective monitoring of shipments is a truly collaborative approach, whereby all stakeholders charged with moving temperature-sensitive cargo work together to develop and implement the required programs.

Parallel Trade

The recent spate of selling pharmaceuticals from Canada into the US is only the tip of the iceberg. Canadian pharmaceutical companies were buying drugs at a lower price negotiated by the Canadian government and selling them across the border into the US where pricing is higher. This also occurs between borders in Europe between large wholesalers, as well as through black market transactions in developing countries. The danger here is that pharmaceutical companies lose the ability to know where these drugs are coming from. This can be largely avoided by the use of RFID technology.

Learn how you can enhance your pharma logistics capabilities.

Recent Posts

new product launch

Attaining New Product Launch Success in the Pharma Industry

A new product launch is one of the biggest expenses incurred by pharma companies worldwide. The right product launch strategy can help ensure that the product is recognized and accepted by physicians, KOL, and patients alike. Pharma companies invest considerable time and money into drug development and clinical trials. In case a new product launch plan does not give the desired results, the burden becomes too heavy on pharmaceutical companies. While the level of clinical differentiation plays an important role in guaranteeing a drug’s success, there are many examples of successful drugs that were not considered a major clinical breakthrough during the product launch. Here are some tried and tested strategies for companies in the pharma industry to improve a new product launch.

A new product launch strategy in the pharma industry today requires greater coordination across the entire organization, including market access, patient services, medical affairs, regulatory, marketing, and sales. Request a free proposal to know how our solutions can help you ensure a successful and smooth new product launch.

New Product Launch Strategies for Pharma Companies

new product launchGo beyond clinical trial results

Today, new product launches in the pharma industry face unprecedented intensity in terms of competition. The average window of time in which a drug remains in the market before competitor products arrive has dropped down from approximately eight years to less than five years. This onslaught of new drugs makes it highly challenging for pharma companies to use phase III clinical trial data alone to differentiate their drug in front of physicians, health insurers, and regulators. Companies can ensure success in the case of a new product launch only if they are adept in communicating both the clinical and non-clinical benefits of a new product to physicians and decision-makers.

Focus on timing

Timing is critical to the success of any new product launch. Pharma companies need to plan and be prepared months ahead of the actual new product launch date. As the launch date gets closer, companies can initiate discussions on social media platforms and forums on the disease that is being targeted. Even after the new product launch, provide actionable content using those exact same channels. Provide scientifically accurate information on how your new product aids in combating the targeted disease and enhancing patient outcomes.

Pharma companies that repeatedly outperform expectations for a new product launch develops new sources of differentiation, focus on building superior customer experiences, and treat drug launches as a micro-battle. Get in touch with our experts to know how our solutions can help you get there.

Build customer advocacy

Physicians generally tend to consider a much wider set of clinical data before prescribing a drug. This includes clinical protocols, drug pricing, and the type of patient to whom the drug should be prescribed, and the treatment regimen involved. According to pharma industry experts at Infiniti, brand preference of most physicians are attributed to customer experience factors beyond the product.This includes factors such as how well pharma companies support physicians by providing answers to medical questions, identifying patients, and connecting physicians with peers.

Learn more about Infiniti’s solutions for companies in the pharma industry

Trends in pharmaceutical industry

Pharmaceutical Industry Challenges to Watch Out for in 2019

Despite several major challenges in the way over the past couple of years, the pharmaceutical industry continues to thrive. However, the sector is not completely free from challenges this year either. Due to the nature of the industry, cost aspects and stricter regulations remain as constant pharmaceutical industry challenges. Furthermore, pharma companies are also under scrutiny by health insurers, consumers, and the government for greater transparency and accountability. In this blog, industry thought leaders from Infiniti Research gives an overview of the current scenario in the pharma industry and also discusses the key pharmaceutical industry challenges that companies can expect this year.

Pharmaceutical industry challenges 2019

Pharmaceutical industry challenges 2019Patent cliffs

The expiry of a drug patent and the consequent drop in the sales of the product which previously held a large market share is known as a patent cliff. These patent cliffs give competitors the opportunity to produce and patent a comparable brand name drug. In the next couple of years, this is going to be one of the key pharmaceutical industry challenges affecting prescription drug sales worldwide.

As the pharma industry becomes increasingly globalized, complex, and highly regulated, the sector must become more streamlined and cost-efficient at manufacturing and distributing its products. Request a free proposal to know how our solutions can help you streamline your operations and overcome critical pharmaceutical industry challenges.

Foreign counterfeit drugs

The increasing flow of foreign counterfeit drugs into the American market is another key challenge that would affect pharma companies in a big way. As several pharmaceutical manufacturers are moving abroad to attain lower costs, it must be ensured that they meet the U.S. quality standards while adhering to the local regulations overseas. It is also essential to block all illegal trafficking of counterfeit medications. In order to achieve this, stringent regulations and standards must be imposed on all vendors and third parties involved in the manufacturing and transportation of pharma products. For pharma companies operating out of or distributing drugs in the UK, Brexit will make it even more difficult.

US drug prices

The issue of rising drug costs in the US continues to persist. The price freezes in 2018 was a result of constant pressure from patients, politicians, and other regulatory bodies. As a result, a proposal was made to introduce an international pricing index through Medicare with the aim of reducing Medicare spending considerably. This proposal was widely criticized due to concerns and to add on to the pharmaceutical industry challenges several companies hiked their prices even further in the early 2019. One of the key pharmaceutical industry challenges in the US right now is to control drug prices and provide more accessible and affordable healthcare to the Americans.

Have unanswered questions about the current pharmaceutical industry challenges and how our solutions can help you formulate effective strategies to overcome them? Get in touch with our experts for queries relating to our services for pharma companies.

Shift to patient-centric healthcare

The advent of technology has made the patients more informed and they are now likely to play a more active role in any treatment plan prescribed by their doctor. While patient-centric healthcare provides several opportunities, it can also add on to the current pharmaceutical industry challenges. The primary challenge will be to determine how to leverage the power of health technology and focus on partnerships directly with the customers rather than with the medical community. In order to survive despite the rising prices, companies in the pharma industry must foster better relationships and build trust with the consumers. Also, the rising consumerism has prompted customers to look at prescriptions from a more value-benefit perspective. As healthcare consumerism rises, pharma companies must find ways to provide real-world research backup claims to justify their products and prices.

Learn more about our market intelligence solutions

Competitor analysis

Top Manufacturing Trends Flourishing in the Pharma Industry

The global economic uncertainties, increasing healthcare costs and expiring patents are putting pharma companies in a state of turmoil. However, on the brighter side, the rapid development of the emerging markets, progress in drug research, the rise in generics production, the availability of high-potency drugs, and innovations in manufacturing trends will sustainably modify the global pharmaceutical landscape. Moreover, the increasing prevalence of chronic diseases and the growing demand for medications, high market growth, new medicines, and therapy forms, changing regulations, and progressing digitization are going to give birth to new manufacturing trends to meet the growing demand.

Manufacturing trends in the pharma industry

Process analytical technology

This initiative sets a legal framework in the USA aiming to motivate pharma companies to improve the production process and achieve consistent quality while reducing waste and costs. In order to comply with this regulation and the changing manufacturing trends, pharma companies need to have systems in place that ensure detailed monitoring of their continuous and batch processes. Process analytical technology is one of the vital manufacturing trends that enables and drives continuous manufacturing. It was identified as one of the most important manufacturing trends in pharma companies along with integrated manufacturing business and automation processes.

banner IR

Digitization and labeling information

Effective tracking, tracing, and labeling is a mandatory proof of authenticity and prevention of drug counterfeiting. Digitization of labeling information has resulted in greater emphasis being placed on collecting, securing, and processing digital data about pharma products.

Low-volume drugs

There are several issues relating to introducing new drugs in the market. This includes manufacturing issues as well, so a review of manufacturing trends in approvals of new molecular entities (NMEs) can provide insight into manufacturing activity. A key trend in NME approvals is the increased share of orphan drugs approved as NMEs. Orphan drugs are defined as drugs that treat diseases which are known to affect 200,000 or fewer people, as defined by the US Food and Drug Administration (FDA). The FDA provides incentives, including market-exclusivity benefits, for developing orphan drugs. Due to a smaller patient population, these drugs are typically produced in lower volumes when compared to primary care drugs.Get More Info

Risk-based manufacturing inspections

The FDA is continuing its plan to use a risk-based selection model for manufacturing inspections in the pharma industry. This forms a part of its strategy to allocate resources more effectively and gain greater parity between inspections of domestic and foreign drug-manufacturing facilities. During September 2018), the FDA published an internal policy that outlines the agency’s risk-based, site-selection model for inspecting foreign drug-manufacturing facilities. The FDA prioritizes inspections of sites regardless of their location with the help of a risk-based site-selection model. This is one of the critical manufacturing trends that pharma companies must watch out for.


Gain more insights into how Infiniti’s solutions can help pharma companies

Contact US

Pharmaceutical Drugs Market Analysis: An Infiniti Research Success Study

Digitalization is fundamentally changing the way the healthcare industry is functioning today. The pharmaceutical drugs market, which is a core part of healthcare, is no exception to this.

New innovations and technologies are already enabling pharmaceutical drugs manufacturers to improve patient care and medicine development. However, healthcare industry players and other customers of pharmaceutical companies are demanding more and better data on the medical efficacy and improved patient quality of life. Such needs and demands cannot be fulfilled by purely traditional means.

Moreover, now that the era of conventional blockbuster pharmaceutical drugs is about to come to an end, the focus is shifting towards high value but lower volume products such as biomedicines and advanced medical devices. Also, the increasing price pressure caused by the competitive market price regulations and patent expirations is forcing pharmaceutical drugs manufacturers to alter their current market and product strategies to survive.

Business Issues

  • The client: Pharmaceutical drugs manufacturer

A renowned pharmaceutical drugs manufacturer – based out of the United States – approached Infiniti Research to conduct a market analysis. The pharmaceutical drugs manufacturer was facing predicaments in assessing the demand and supply for their products. Additionally, they wanted to gain relevant insights into the popular treatments and forecast the market’s growth prospects. The client also wanted to tap potential opportunities in the pharmaceutical drugs market and penetrate across niche segments.

How Can Market Analysis Engagement Help Pharmaceutical Drugs Manufacturers?

A robust market analysis engagement helps pharmaceutical drugs manufacturers outline various customer segments and their buying patterns, and also recognize the economic environment in terms of the barriers to entries and regulations. Additionally, healthcare industry players can identify the attractiveness of a particular market and the potential bottlenecks hindering the market’s growth.

Summary of our market analysis solution

Ask An Analyst


Client Journey

To analyze the shift towards better patient engagement, the market analysis experts followed a comprehensive qualitative and quantitative research methodology. The experts also compiled information from proprietary sources, including industry databases, company forums, and newsletters to help the client gain detailed insights into the pharmaceutical drugs market.

The Solution Benefits and the Business Impact

The market analysis solution offered by Infiniti assisted the client in gaining detailed insights into the pharmaceutical drugs market in terms of the size, the growth prospects, and trends. Moreover, with the aid of this market analysis engagement, the pharmaceutical drugs manufacturer was able to profile the most appropriate customers and understand the latest technological developments taking place in the global healthcare industry.

The Future

Pharmaceutical drugs manufacturers around the globe are now realizing that it is not enough anymore to produce and develop drugs. New trends now show that they are expected to go beyond the physical appearance of the medicine itself and offer a complete package. For instance, a latest trend called the “around the pill”, a digital offering including digital health apps that could be prescribed by a doctor or bundled with a drug is something that we could expect in the coming years.


A must-read case study for strategy specialists and decision makers looking to develop an understanding of the global healthcare industry

Request Proposal


Related Posts:

Market Opportunity Assessment for a Leading Pharma Market Client

The recently unfolded challenges have drastically changed the pharma landscape leading to drug approval stagnation and diminished R&D productivity.

The pharma market is well-known for innovation- new and advanced pharmaceutical drugs are incessantly being discovered and marketed across the globe. In addition, mergers and acquisitions are taking place on a regular basis and new studies are being conducted regularly by the pharmaceutical drugs manufacturing companies to enhance their product portfolio.

In addition, the rapidly changing technical landscape has leveraged the shift toward a more patient-centric healthcare, as evidenced by telemedicine and wearable biometric devices. However, patient-centric care has proven to be rewarding as well as challenging for pharma companies. Even with the recently unfolded challenges changing the pharma landscape, there are promising opportunities on the horizon with patient-centric healthcare trends and biosimilars that are likely to accelerate market growth.

The Business Challenge

  • The client: A pharmaceutical drugs manufacturing company

To identify and quantify the opportunities in the pharma market, the client – a leading pharmaceutical drugs manufacturing company – approached Infiniti to conduct a market opportunity assessment. The client wanted to identify and gauge the attractiveness of business opportunities in the pharma market. Lack of visibility regarding market conditions posed a major challenge for the client as they were unable to define a clear business strategy and justify their actions. Therefore, their primary objective was to identify new opportunities by determining the market factors affecting their business growth.

How Can Market Opportunity Assessment Help Pharmaceutical Drugs Manufacturing Companies?

Understanding and gaining detailed insights into market opportunities is essential for any organization A detailed market opportunity assessment acts as a cornerstone of a successful business strategy and also helps identify new market opportunities. However, it doesn’t necessarily require huge investments in terms of time and energy. By investing in market opportunity assessment, pharmaceutical drugs manufacturer can create a basic framework necessary for- making data-driven decisions, resource optimization, and increase brand perception.


Summary of our market opportunity assessment

Pharma Market

Ask An Analyst


Client Journey

Infiniti’s market opportunity assessment helped the pharma market client gain a detailed industry outlook. It also helped the client identify major market opportunities along with the trends and implications for each opportunity.

Furthermore, to help the client assess the competitive landscape and identify imminent market trends, the market experts at Infiniti conducted a detailed market opportunity assessment to determine customer needs and accordingly deliver the products to enhance customer satisfaction. The approach included primary and secondary research methodologies coupled with qualitative and quantitative data collection procedures. The experts also reached out to various stakeholders in the pharma market.

Solution Benefits and the Business Impact

Infiniti’s market research experts helped the pharmaceutical drugs manufacturing company accomplish their organizational objectives, leading to an increase in market share. The market opportunity assessment also helped the client keep tabs on market opportunities to enhance their product and services offerings. Moreover, the solutions offered helped in expanding their business in existing as well as new markets.

The Future

With the rapid growth in the pharma market, it might be difficult for pharmaceutical drugs manufacturers to gauge the attractiveness of market opportunities. In order to withstand the growing competitive pressure, leading players in the pharma market are increasingly investing in other alternatives such as – industry partnerships, capacity expansions, market opportunity assessments, and mergers and acquisitions.


A must-read case study for strategy specialists and decision makers looking to develop an understanding of the global pharma market.

Request Proposal


Related Posts:

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice